Consensus Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe 06:37:19 2023-09-22 am EDT Intraday chart for Novartis AG 5-day change 1st Jan Change
91.96 CHF -0.81% -0.30% +10.04%

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History : Analyst Recommendations

a3906579ab89746.rl9t6FM1ZMlpGa3c0xFKQzdBBEoUlBKKXmCkYdJZ8zY.72tV3RhSNZZebefv5SQmclR4Ux1lx0a-Cj_nEqUuy3rAGCC5FnQQuTpK4A~57e0ad78ff62acfb91bf7663be23df26
NOVARTIS AG : Deutsche Bank gives a Buy rating MD
Fitch Assigns Rating to Bausch + Lomb's Secured Term Loan, Secured Bond; Up 1.4% MT
NOVARTIS AG : Deutsche Bank reiterates its Buy rating MD
NOVARTIS AG : Jefferies maintains a Buy rating MD
NOVARTIS AG : Deutsche Bank gives a Buy rating MD
NOVARTIS AG : Gets a Buy rating from Deutsche Bank MD
NOVARTIS AG : JP Morgan remains Neutral MD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating MD
NOVARTIS AG : Barclays maintains a Sell rating MD
Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target MT
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation MT
AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation MT
NOVARTIS : Healthy operating momentum pushes expectations higher Alphavalue
DZ Bank AG Research Lowers Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : Deutsche Bank remains its Buy rating MD
NOVARTIS AG : JP Morgan reiterates its Neutral rating MD
NOVARTIS : Momentum sustained in Q2; another guidance upgrade Alphavalue
NOVARTIS AG : UBS reiterates its Neutral rating MD
NOVARTIS AG : JP Morgan reiterates its Neutral rating MD
NOVARTIS AG : Gets a Buy rating from Jefferies MD
HSBC starts majority of pharma stocks with 'Buy' - Bayer, however, 'Reduce DP
NOVARTIS AG : Gets a Buy rating from Deutsche Bank MD
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation MT
NOVARTIS AG : Jefferies remains its Buy rating MD
Fitch Maintains Novartis Rating on Strong Organic Growth MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
102.65USD
Average target price
113.28USD
Spread / Average Target
+10.36%
High Price Target
129.45USD
Spread / Highest target
+26.11%
Low Price Target
89.43USD
Spread / Lowest Target
-12.88%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

DEUTSCHE BANK RESEARCH Emmanuel Papadakis
JEFFERIES Peter Welford
JPMORGAN Richard Vosser
BARCLAYS Emily Field
Barrington Research
AlphaValue
DZ Bank
UBS Michael Leuchten
Stifel Nicolaus
International Strategy & Investment Group
Credit Suisse
Morningstar
Kepler Capital Markets
ODDO BHF
GOLDMAN SACHS Keyur Parekh
BERENBERG Kerry Holford
DA Davidson
MORGAN STANLEY Mark Purcell
Zacks Equity Research
BNP Paribas
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Berenberg Bank
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER Eric Le Berrigaud
LIBERUM CAPITAL Graham Doyle
BANK OF AMERICA (BOFA) Graham Parry
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
-40% off #SeptemberDeals : Our subscriptions help you find hidden investment opportunities.
Subscribe
fermer